CardioCell

CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products.

Founded in San Diego, Calif., in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique patented ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell has an exclusive worldwide license from its parent company, Stemedica, for exploration of therapeutic indications in the cardiovascular field, which includes such indications as acute myocardial Infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD).